Pharmacovigilance in 2026 – What is Expected to Change in the Regulatory Landscape Across Regions?

Blog Details

Pharma manufacturers are rapidly launching their products across borders, directly intensifying the burden on safety monitoring. On the other hand, to enable quick signal detection, the PV processes are closely integrated with emerging technologies such as Artificial Intelligence, digital reporting platforms, and real-world evidence (RWE), which are recommended for inclusion in regulatory frameworks. The shift for this rapid safety intelligence requires proactive approaches rather than reactive compliance. Hence, learning about the global landscape of mandatory Pharmacovigilance is critical. Here, we give you a few key Pharmacovigilance (PV) mandates to look into in 2026 across key global regions. 

What’s Expected to Change in the EU Pharmacovigilance (PV) Landscape?

The EU remains the torchbearer of PV regulation. As you may know, in July 2025, the European Commission (EC) adopted Implementing Regulation (EU) 2025/1466. A significant amendment to existing legislation is scheduled to come into practice on 12th of February 2026.

It is expected that, with this change, there will be greater emphasis on quality, transparency, and standardized reporting to streamline regulatory decisions across all EU member states.

Key Considerations:

  • The burden of documentation will be reduced in the Pharmacovigilance System Master File (PSMF). The new legislation demands only critical deviations from the standard PV procedures to be documented in the PSMF.
  • Subcontractors’ safety responsibilities should be explicitly defined in the contracts. The responsibilities might range from data exchange requirements to audit rights. In a way, it gives strict control over third parties.
  • Market Authorization Holders (MAHs) will need to continuously monitor data in EudraVigilance to detect signals promptly. They are entitled to quickly validate the signals.
  • Periodic safety update reports (PSURs) will be required to report on risk management effectiveness, and post-authorisation safety studies (PASS) must be electronically registered before data collection. 

What’s Expected to Change in the US Pharmacovigilance Landscape?

In the United States, the FDA’s regulatory framework for pharmacovigilance remains unchanged, and it continues to refine the Good Pharmacovigilance Practices (GVP) in step with new innovations and patient safety. The health authority continues to oversee PV activities through previously established post-marketing reporting regulations. It also includes Title 21 of the Code of Federal Regulations (CFR). However, in 2026, there will be greater emphasis on electronic reporting and structured safety data. For serious adverse events, expedited timelines will apply.

Key Considerations:

  • Electronic submission of serious adverse event reports to FAERS (FDA database) will be mandatory.
  • Safety signal identification and communication will heavily depend on the use of real-world data and analytics.
  • Regulations will closely align with ICH guidance. 
Baghdad, IQ
Nov 19, 2026
weather image
18
°C
broken clouds

Contact Info

Baghdad, Iraq / Arasat Al Hindiya, Z.925, St.13, H. 18/2/1

Cart (0 items)
Toggle Dark Mode
Select the fields to be shown. Others will be hidden. Drag and drop to rearrange the order.
  • Image
  • SKU
  • Rating
  • Price
  • Stock
  • Availability
  • Add to cart
  • Description
  • Content
  • Weight
  • Dimensions
  • Additional information
Click outside to hide the comparison bar
Compare